Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Peripheral Artery Disease I: Introduction

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

Peripheral Artery Disease V: Postoperative Nursing Management

Peripheral Artery Disease V: Postoperative Nursing Management

During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.

ESMO open·2024

Same author

Regional and annual patterns in respiratory virus co-infection etiologies and antibiotic prescriptions for pediatric mycoplasma pneumoniae pneumonia.

European review for medical and pharmacological sciences·2022

Same author

Onychopapilloma: its clinical, dermoscopic and pathologic features.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

Same author

Volumetric Measurement of Relative CBV Using T1-Perfusion-Weighted MRI with High Temporal Resolution Compared with Traditional T2*-Perfusion-Weighted MRI in Postoperative Patients with High-Grade Gliomas.

AJNR. American journal of neuroradiology·2022

Same author

Recovery from Cranial Nerve Symptoms after Flow Diversion without Coiling for Unruptured Very Large and Giant ICA Aneurysms.

AJNR. American journal of neuroradiology·2022

Same author

Intraindividual Comparison between the Contrast-Enhanced Golden-Angle Radial Sparse Parallel Sequence and the Conventional Fat-Suppressed Contrast-Enhanced T1-Weighted Spin-Echo Sequence for Head and Neck MRI.

AJNR. American journal of neuroradiology·2021

Search research articles

Related Experiment Video

Updated: May 31, 2026

Embryonic Stem Cell-Derived Endothelial Cells for Treatment of Hindlimb Ischemia

Embryonic Stem Cell-Derived Endothelial Cells for Treatment of Hindlimb Ischemia

Published on: January 23, 2009

Stem-cell therapy for peripheral arterial occlusive disease.

A-K Kim¹, M-H Kim, S Kim

¹Division of Vascular Surgery, Sungkyunkwan University School of Medicine, Samsung Medical Center, Kangnam-gu, Seoul 135-710, Republic of Korea.

European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery

|July 19, 2011

Summary

Human cord blood-mononuclear cells (HCB-MNCs) show promise for treating ischemic limbs. Animal studies confirmed effectiveness, and early clinical trials indicated safety, with no adverse events observed in patients.

More Related Videos

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

Related Experiment Videos

Last Updated: May 31, 2026

Embryonic Stem Cell-Derived Endothelial Cells for Treatment of Hindlimb Ischemia

Embryonic Stem Cell-Derived Endothelial Cells for Treatment of Hindlimb Ischemia

Published on: January 23, 2009

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

Area of Science:

Regenerative Medicine
Vascular Biology
Stem Cell Therapy

Background:

Limb ischemia poses a significant clinical challenge, often leading to amputation.
Developing effective and safe cell-based therapies for ischemic conditions is a critical research area.

Purpose of the Study:

To evaluate the therapeutic potential of human cord blood-mononuclear cells (HCB-MNCs) for limb ischemia.
To assess both the efficacy in preclinical models and the safety in human subjects.

Main Methods:

A dose-response animal study using a canine limb ischemia model to evaluate angiogenic responses to HCB-MNCs.
A case series of seven patients with thromboangiitis obliterans treated with HCB-MNCs, monitoring for graft-versus-host disease and other complications.

Main Results:

HCB-MNC transplantation significantly increased capillary density, angiogenic gene expression, and angiogenic factors in animal ischemic limbs.
No instances of graft-versus-host disease or cardiac/cerebral complications were reported in the seven treated patients during the follow-up period.

Conclusions:

Preliminary findings suggest HCB-MNCs are a potentially safe source of stem cells for treating ischemic limbs.
Further extensive clinical research is warranted to confirm long-term safety and efficacy of HCB-MNC transplantation.